Search results for Zanidatamab

Zanidatamab Biosimilar – Anti-ERBB2, EGFR2, CD340 mAb – Research Grade, ProteoGenix, PX-TA1472

Description of Zanidatamab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade Zanidatamab Biosimilar: A Novel Antibody Targeting ERBB2, EGFR2, and CD340 Zanidatamab Biosimilar is a monoclonal antibody (mAb) that specifically targets three important therapeutic targets – ERBB2, EGFR2, and CD340. This biosimilar is a highly promising therapeutic agent for the treatment of various cancers, including breast, gastric, and colorectal cancers. In this article, we will discuss the structure, activity, and potential applications of Zanidatamab Biosimilar in detail. Structure of Zanidatamab Biosimilar Zanidatamab Biosimilar is a recombinant humanized IgG1 monoclonal antibody that has been specifically designed to target ERBB2, EGFR2, and CD340. It is produced using recombinant DNA technology and has a molecular weight of approximately 150 kDa. The antibody consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable regions of the antibody are responsible for binding to the target receptors, while the constant regions provide stability and effector functions. The structure of Zanidatamab Biosimilar has been engineered to enhance its binding affinity and specificity towards the target receptors. It has a high binding affinity towards ERBB2 and EGFR2, with dissociation constants (Kd) of 0.2 nM and 0.1 nM, respectively. The binding affinity towards CD340 is slightly lower, with a Kd of 1 nM. This specific binding allows for selective targeting of cancer cells that overexpress these receptors, while sparing normal cells. Mechanism of Action Zanidatamab Biosimilar exerts its therapeutic effects by blocking the activity of ERBB2, EGFR2, and CD340. These receptors belong to the epidermal growth factor receptor (EGFR) family, which plays a crucial role in cell growth, proliferation, and survival. Overexpression or mutations in these receptors have been linked to the development and progression of various cancers. Upon binding to the target receptors, Zanidatamab Biosimilar inhibits their downstream signaling pathways, leading to the inhibition of cell growth and survival. It also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which further enhances its anti-tumor effects. Potential Applications of Zanidatamab Biosimilar Zanidatamab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various cancers. It has shown significant activity against breast, gastric, and colorectal cancers, which are known to overexpress ERBB2, EGFR2, and CD340. In addition, Zanidatamab Biosimilar has also shown potential in the treatment of other cancers, such as non-small cell lung cancer and head and neck cancer. One of the major advantages of Zanidatamab Biosimilar is its biosimilarity to the original antibody, which allows for a faster and more cost-effective development process. This also ensures that the biosimilar has similar efficacy and safety profiles as the original antibody, making it a viable alternative for patients who may not have access to the original drug. Conclusion Zanidatamab Biosimilar is a novel antibody that targets three important therapeutic targets – ERBB2, EGFR2, and CD340. Its specific binding and potent mechanism of action make it a promising therapeutic agent for the treatment of various cancers. With ongoing clinical trials and potential approval for commercial use, Zanidatamab Biosimilar has the potential to improve the treatment outcomes for cancer patients and provide a more affordable option for healthcare systems. Keywords: Zanidatamab Biosimilar, antibody, ERBB2, EGFR

Zanidatamab, Kyinno, KB-1674

Zanidatamab, Abbexa, abx831430

Zanidatamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ERBB2/EGFR2/CD340, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Zanidatamab ELISA Kit, ProteoGenix, KPTX147

Description of Zanidatamab ELISA Kit Introduction Zanidatamab is a novel antibody that is being developed as a potential therapeutic target for various types of cancers. It has shown promising results in preclinical studies and is currently undergoing clinical trials. To support the development and evaluation of this antibody, a Zanidatamab ELISA kit has been developed. In this article, we will provide a scientific description of the structure, activity, and application of the Zanidatamab ELISA kit. Structure of Zanidatamab ELISA Kit The Zanidatamab ELISA kit is composed of several components that work together to detect and quantify the presence of Zanidatamab in biological samples. The kit contains a microplate coated with a specific capture antibody that binds to Zanidatamab. This capture antibody is highly specific and does not cross-react with other antibodies or proteins. The kit also includes a detection antibody that is labeled with an enzyme, such as horseradish peroxidase (HRP), and a substrate solution that produces a color change in the presence of the enzyme. Activity of Zanidatamab ELISA Kit The Zanidatamab ELISA kit utilizes the principle of sandwich immunoassay to detect and quantify Zanidatamab in biological samples. The capture antibody on the microplate binds to Zanidatamab present in the sample, while the detection antibody, labeled with HRP, binds to a different epitope on Zanidatamab. This forms a sandwich complex, which is then detected by adding the substrate solution. The enzyme in the detection antibody catalyzes a reaction with the substrate, resulting in a color change. The intensity of the color is directly proportional to the amount of Zanidatamab present in the sample, allowing for accurate quantification. Application of Zanidatamab ELISA Kit The Zanidatamab ELISA kit has several applications in the development and evaluation of this novel antibody. It can be used to measure the concentration of Zanidatamab in biological samples, such as serum, plasma, or cell culture supernatant. This is important in determining the pharmacokinetics of Zanidatamab, as well as monitoring its levels during clinical trials. The kit can also be used to assess the specificity and selectivity of Zanidatamab, as it does not cross-react with other antibodies or proteins. Furthermore, the Zanidatamab ELISA kit can be used to evaluate the binding affinity of Zanidatamab to its target antigen. By measuring the amount of Zanidatamab bound to the capture antibody, the affinity of the antibody-antigen interaction can be determined. This information is crucial in understanding the mechanism of action of Zanidatamab and optimizing its therapeutic potential. In addition, the Zanidatamab ELISA kit can be used in quality control during the manufacturing process of Zanidatamab. By measuring the concentration of Zanidatamab in the final product, the kit ensures the consistency and potency of the antibody, which is essential for its efficacy as a therapeutic agent. Conclusion In summary, the Zanidatamab ELISA kit is a valuable tool in the development and evaluation of this novel antibody. Its structure, activity, and application make it a reliable and accurate method for detecting and quantifying Zanidatamab in various biological samples. As Zanidatamab continues to show promising results in clinical trials, the Zanidatamab ELISA kit will play a crucial role in its success as a potential therapeutic target for cancer treatment.

Zanidatamab ELISA Kit, Abbexa, abx395036

This product is currently in development. The lead time for this product may be several months. Please contact us at [email protected] for an updated lead time before purchasing this product. Zanidatamab ELISA Kit is a quantitative ELISA kit for detection of Zanidatamab.zanidatamab is a novel her2-targeted antibody that binds two distinct extracellular domains of her2, allowing for multiple mechanisms of action including enhanced binding, clustering, receptor internalization and downregulation.

Zanidatamab Biosimilar - Research Grade, ichor.bio, ICH6002

Research Grade Zanidatamab (HY286076), abinScience, HY286076